- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

New drugs for Alzheimer’s are finally coming onto the market after decades of failed attempts to slow its devastating progression. But startup Cognito Therapeutics is taking a drug-free approach to ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying ...

Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...

Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX Ventures, bringing its total ...

Please provide your email address to receive an email when new articles are posted on . Neurotechnology company Cognito Therapeutics announced a partnership with Aetion to develop a validated ...